Navigation Links
Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
Date:3/25/2009

- Journal of Clinical Lipidology publishes largest study comparing cancer risk of ezetimibe and ezetimibe/simvastatin to statin therapies using FDA database -

BOSTON, March 25 /PRNewswire-USNewswire/ -- A new study shows no increased cancer risk with ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to cancer rates of other powerful lipid-lowering statin therapies. The study, conducted by Tufts Medical Center lipid and health policy experts, was published in the April issue of the Journal of Clinical Lipidology (www.lipidjournal.com).

"This real-world examination shows no increased risk to patients taking ezetimibe alone or the ezetimibe/simvastatin combination to lower their lipid levels -- an issue that sparked many policy and health safety conversations," said lipidologist Richard Karas, MD, PhD, Professor of Medicine, Tufts University School of Medicine and Associate Director, Molecular Cardiology Research Institute, Tufts Medical Center, who co-authored the study along with Tufts Medical Center colleague, Alawi A. Alsheikh-Ali, MD, Institute for Clinical Research and Health Policy Studies.

Researchers at Tufts Medical Center and Tufts University School of Medicine studied rates of reports of cancer as an adverse event filed with the U.S. Food and Drug and Administration (FDA) for patients taking ezetimibe or ezetimibe/simvastatin compared to patients on mono-therapy with simvastatin, atorvastatin or rosuvastatin, during a four-year period. This is the first study to use the FDA database to evaluate potential cancer risk of cholesterol-lowering medications.

The Tufts researchers found 2,334 cases of cancers reported in the total population studied. Cancer rates were analyzed accounting for the number of prescriptions for each treatment dispensed across the country, based on a total of 559 million prescriptions for all of the cholesterol-lowering medications evaluated. The analysis found cancer reported in 2.9 per million prescriptions for ezetimibe, 1.3 per million prescriptions for ezetimibe/simvastatin therapy and an average of 4.1 per million prescriptions for other lipid lowering treatment. These rates demonstrate no increase in cancer for ezetimibe and ezetimibe/simvastatin regimen versus the other treatments studied.

"These data will hopefully return the conversation between physicians and patients back toward the most pressing public health risk in America -- unmanaged high LDL that can result in heart disease or stroke -- the nation's number one and number three killers," continued Dr. Karas.

This research, which explored three times more cancers than analyzed by Sir Richard Peto from the SEAS, SHARP and IMPROVE-IT studies published in the New England Journal of Medicine, September 2, 2008, is consistent with Peto's final report supporting no credible evidence that ezetimibe or ezetimibe/simvastatin increase the risk of developing cancer.

Funding Sources and Disclosures

No specific corporate funding was requested or obtained for data collection, analysis and publication of these findings. Dr. Karas has received speaker's fees and/or consulting fees from Merck, Abbott, and Schering-Plough. Dr. Alsheikh-Ali is a recipient of a faculty development award from Pfizer/Tufts Medical Center.


'/>"/>
SOURCE Tufts Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
2. Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
3. Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
4. Drug Combo Could Lower Diabetes Complications and Costs
5. CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth
6. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
7. Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
8. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
11. Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... BARBARA, Calif. and INDIANAPOLIS ... (NYSE: LLY ) and the William Sansum ... the lives of Latino people affected by diabetes through ... tremendous burden of diabetes and cardiovascular disease bears a ... United States ," said David Kerr , ...
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... MOINES, Iowa , March 23, 2017   ... and career resource, has partnered with Indiana Biosciences ... Indiana organizations and educational institutions to bring ... with the first-ever BioIndiana Hotbed map, an artistic representation ... framed print was presented to Vice President Mike ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... “The Communion of Saints: A Pastor’s Potpourri ... congregations across the United States. “The Communion of Saints” is the creation ... served congregations in seven states throughout his long career of devotion to the ...
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Texas ... located at 960 Gruene Road in Building 2. The clinic is the group’s second ... Bennett, PT, says opening the company’s second New Braunfels location brings things full circle ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
Breaking Medicine News(10 mins):